Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612 is registered in ClinicalTrials.gov with BriaCell Therapeutics Corporation as lead sponsor.

NCT NCT06072612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06072612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Lead sponsor
BriaCell Therapeutics Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
December 5, 2023
Completion date
June 30, 2028
Enrollment
404 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer metastatic, breast neoplasm, end stage cancer, metastatic breast cancer